advanced search

INJECTION

RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES
EXPERT VIEW
Dan Lock
RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES
Dan Lock explores how the experiences and motivations of individuals using glucagon-like peptide 1 drugs for weight loss may differ from those managing diabetes or heart disease.
ADVANCING SUBCUTANEOUS INFUSION THERAPY FOR PATIENTS THROUGH INNOVATION AND PARTNERSHIPS
INJECTION
Julien Vandewalle
Convatec
ADVANCING SUBCUTANEOUS INFUSION THERAPY FOR PATIENTS THROUGH INNOVATION AND PARTNERSHIPS
Julien Vandewalle and Clare Holden explain Convatec’s long-term partnerships with pharmaceutical and medical device companies are driving development in chronic care by introducing subcutaneous technologies that support the treatment of conditions such as diabetes and Parkinson’s disease – showcasing Convatec’s Neria™ Guard infusion set.
Interview: Understanding the Impact of USP<382> on Primary Packaging Development
INTERVIEW
Dr Laure-Helene Guillemot
Aptar Pharma
Interview: Understanding the Impact of USP<382> on Primary Packaging Development
Laure-Hélène Guillemot discusses the new USP <382> chapter coming into force on December 1st, 2025, which will significantly transform functional testing protocols for pharmaceutical companies.
THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS
WEARABLES
Mary Lou Glotzbach
Grand River Aseptic Manufacturing
THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS
Mary Lou Glotzbach and Dr Greg Moakes consider the implications of the increasing demand for high-volume injections across the drug delivery industry, and how technologies such as wearable injectors are creating novel challenges for the fill-finish process due to the novel containers involved, making the case that it is only through clear communication and close collaboration between partners that these challenges can be met and surmounted.
PROTECTION AND PRODUCTION: OPTIMISING PRIMARY PACKAGING SOLUTIONS FOR mRNA THERAPIES
INJECTION
Enrico Barichello
Stevanato Group
PROTECTION AND PRODUCTION: OPTIMISING PRIMARY PACKAGING SOLUTIONS FOR mRNA THERAPIES
Enrico Barichello and Riccardo Prete discuss the impact that mRNA-based therapies are having on the modern pharmaceutical market and how these delicate therapies require careful handling, with a particular focus on how Stevanato’s portfolio of primary packaging products can be highly beneficial when bringing these critical medicines to market.
NEXT-GENERATION SURFACE TECHNOLOGIES FOR MEDICAL INJECTION MOULDING
INJECTION
Rob Doorakkers
IGS GeboJagema
NEXT-GENERATION SURFACE TECHNOLOGIES FOR MEDICAL INJECTION MOULDING
Rob Doorakkers of IGS GeboJagema, and Stephan Plassmann of Gloss & Coating, discuss their new Translatio-Coating technology for treating the surfaces of steel parts to achieve microscopic levels of optimisation and open new possibilities for efficiency and quality in drug delivery device manufacturing.
VYTAL – ONE STEP INTO THE FUTURE OF CONTAINER-CLOSURE SYSTEMS
INJECTION
Ana Isabel Gutierrez
H&T Presspart
VYTAL – ONE STEP INTO THE FUTURE OF CONTAINER-CLOSURE SYSTEMS
Ana Isabel Gutierrez looks at advancements in sterile and aseptic filling methods in the pharmaceutical industry, introducing H&T Presspart's Vytal® snap-fit container-closure system, which is designed to meet the growing regulatory demands of the pharmaceutical industry.
GREATER FORMULATION FREEDOM WITH A NOVEL AUTOINJECTOR PLATFORM THAT EXTENDS VOLUME AND VISCOSITY LIMITS
INJECTION
Prof Sigrid Saaler-Reinhardt
Gerresheimer
GREATER FORMULATION FREEDOM WITH A NOVEL AUTOINJECTOR PLATFORM THAT EXTENDS VOLUME AND VISCOSITY LIMITS
Prof Sigrid Saaler-Reinhardt, Dr Andrea Lennerz, Moritz Mond and Marie Stockton discuss how the Gx Inbeneo® autoinjector overcomes the limitations of prefilled syringe-based autoinjectors to provide effective, safe administration of large-volume, high-viscosity formulations.
YES, PEN INJECTORS CAN ACCOMMODATE MORE THAN JUST INSULIN
INJECTION
Cecile Gross
Nemera
YES, PEN INJECTORS CAN ACCOMMODATE MORE THAN JUST INSULIN
Cécile Gross and Mark Tunkel explore the benefits of pen injectors, highlighting their versatility and ease of use, and introduce Nemera’s novel platforms and how they can be adapted for a wide range of indications, enhancing treatment options and the patient experience.
TRANSFORMING PARENTERAL DELIVERY: KEY CONSIDERATIONS FOR SC AND IM FORMULATION DEVELOPMENT
INJECTION
Jeff Clement
PCI Pharma Services
TRANSFORMING PARENTERAL DELIVERY: KEY CONSIDERATIONS FOR SC AND IM FORMULATION DEVELOPMENT
Jeff Clement of PCI looks at the changing landscape of parenteral delivery, considering the pros and cons of intravenous, subcutaneous and intramuscular formulations and considers how new technologies are reshaping the drug delivery landscape.
Product Showcase: CCBIO’S INJECTOR PLATFORM PRODUCTS
INJECTION
Jimmy Fan
CC Bio
Product Showcase: CCBIO’S INJECTOR PLATFORM PRODUCTS
CCBio’s expanding portfolio of self-injection devices reflects the growing importance of at-home administration in driving adherence across a range of therapies. This showcase explores the clinical rationale behind self-injection and details CCBio’s latest innovations, including electronic-assisted devices and Taiwan-based automated assembly.
DRIVING SUSTAINABILITY IN DRUG DELIVERY DEVICE DESIGN AND MANUFACTURING
SUSTAINABILITY
Martin Høier Thomsen
MGS Mfg Group
DRIVING SUSTAINABILITY IN DRUG DELIVERY DEVICE DESIGN AND MANUFACTURING
Martin Høier Thomsen discusses the need for the pharma industry to rise to the challenges of meeting its sustainability goals, explaining how MGS’ expertise and established practices to drug delivery device design and manufacture present a forward-thinking approach to achieving this aim.
OPTIMISING HIGH-DOSE DELIVERY: SYRINGE-AUTOINJECTOR INTEGRATION, INJECTION TIME AND PERFORMANCE
INJECTION
Thomas Blaser
Ypsomed
OPTIMISING HIGH-DOSE DELIVERY: SYRINGE-AUTOINJECTOR INTEGRATION, INJECTION TIME AND PERFORMANCE
Thomas Blaser and Dr Maëlle Douaire explore how drug viscosity, autoinjectors and syringes affect the administration of injectable therapies, demonstrating the results of a study evaluating combined autoinjectors and syringes from the two companies that provide efficient and smooth delivery of high-dose therapies.
CRITICAL LESSONS LEARNED: STRATEGIC PLANNING FOR DRUG DELIVERY SYSTEMS
INDUSTRIALISATION
Dr Steve Badelt
BlueRidge Life Sciences
CRITICAL LESSONS LEARNED: STRATEGIC PLANNING FOR DRUG DELIVERY SYSTEMS
Dr Steve Badelt of Suttons Creek, a BlueRidge Life Sciences company, discusses how the differing cultures and mindsets common to drug development and device design need to be brought together to achieve a smooth and successful combination product development programme, and explores some best practices for achieving optimal outcomes.
A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors
INTERVIEW
Dr Patrick Anquetil
Portal Instruments
A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors
In this exclusive interview with ONdrugDelivery’s Guy Furness, Dr Patrick Anquetil offers insight into the extensive waste involved in the self-injection market. He explains how pivoting from a model focused on fully disposable devices to reusable electromechanical autoinjectors could offer a more sustainable and cost-effective path forward.
UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS
SUSTAINABILITY
Stevanato Group
UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS
Stevanato Group examines how semi-reusable, modular designs like its Vertiva 10 mL on-body delivery system can reconcile patient demands for ease of use with growing expectations for sustainability, sharing new UK preference data and lifecycle analysis that reveal significant waste and emissions reductions.
SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND
SUSTAINABILITY
Lorenzo Biasio
Ypsomed
SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND
Lorenzo Biasio and Gloria Skibba discuss the integration of Ypsomed’s Net Zero Program into its self-injection platforms. With the evolution of GLP-1 therapies and the exploration of higher-dose formulations, the demand for higher-volume autoinjectors is increasing; this article explains how Ypsomed has also applied its sustainability principles to larger-volume delivery.
A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS
OCULAR
Dr Reza Abedian
Gerresheimer
A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS
Dr Reza Abedian, Marie Stockton and Bernd Zeiss consider the complexities and clinical unmet needs of intravitreal injections and discuss how Gerresheimer’s syringe technology can help overcome these challenges.
GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES
EXPERT VIEW
Dr Joe Batley
GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES
Joe Batley and Lorna Barron provide an overview of the latest cutting-edge ophthalmic delivery methods and discuss possible future developments.
A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE
OCULAR
Dr Anu Prabhathachandran
West Pharmaceutical Services
A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE
Anu Prabhathachandran, Menachem Peretz and Manali Potnis discuss the growing need for more effective delivery of ophthalmic therapeutics to meet the needs of the ageing population, including how delivery into the suprachoroidal space may present an appealing alternative to intravitreal injection. They introduce West Pharmaceutical Service’ Suprachoroidal Advanceable Microneedle Device, which offers several advantages for overcoming the challenges with suprachoroidal space.
INTRODUCING THE TERUMO INJECTION FILTER NEEDLE – A FIRST STEP OF THE INFINO™ DEVELOPMENT PROGRAMME
INJECTION
Thomas Isaac
Terumo Medical Care Solutions
INTRODUCING THE TERUMO INJECTION FILTER NEEDLE – A FIRST STEP OF THE INFINO™ DEVELOPMENT PROGRAMME
Thomas Isaac considers the issues associated with injection to highly sensitive areas, such as the vitreous body, and the potential to optimise needle design and features to address these issues, discussing the key features of Terumo’s Injection Filter Needle, indicated for hypodermic and intravitreal injections within this context.
THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS
INJECTION
Dr Andreas Schneider
Ypsomed
THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS
Andreas Schneider and Jakob Lange consider the SC administration of larger volumes of biopharmaceuticals in the pharma industry and summarise a recent study that reviews clinical-stage and approved IV and SC biopharmaceuticals to provide valuable guidance for new product development, as well as for marketing and commercialisation strategies in the rapidly evolving large-volume SC landscape.
CONTAINER SELECTION FOR A HIGHLY SENSITIVE DRUG PRODUCT: A SUCCESS STORY
INJECTION
Enrico Barichello
Stevanato Group
CONTAINER SELECTION FOR A HIGHLY SENSITIVE DRUG PRODUCT: A SUCCESS STORY
Enrico Barichello discusses Stevanato Group’s collaboration with a leading pharmaceutical company to identify a suitable container for a high-concentration monoclonal antibody. The partnership addressed key challenges and contributed to maintaining the drug’s stability and integrity throughout its lifecycle.
DRUG DELIVERY TRENDS FOR 2025
EXPERT VIEW
Tom Oakley
DRUG DELIVERY TRENDS FOR 2025
Tom Oakley and Alex Vasiev look back at how the trends anticipated for 2024 played out in reality and look forward to four major trends expected to influence the drug delivery industry in 2025.
Top